No FDA Funding Boost In Senate HELP GOP Members' Innovation Bill
This article was originally published in The Tan Sheet
HELP Chairman Alexander says FDA should receive gradual appropriations increases, rather than part of "surge" in funding proposed for NIH.
You may also be interested in...
Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.